JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case Report

Ann Intern Med. 2021 May;174(5):719-721. doi: 10.7326/L20-1051. Epub 2021 Jan 12.

Authors

Martin Killian¹, Sébastien Viel², Emilie Chalayer³, Fabien Forest¹, Sylvain Grange¹, Pierre-Benoit Bonnefoy¹, Eric Oksenhendler⁴, Pascal Cathébras¹, Stéphane Paul¹

Affiliations

¹ Centre Hospitalier Universitaire de Saint-Etienne and Université Jean Monnet, Université de Lyon, Saint-Etienne, France.
² Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
³ Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
⁴ Hôpital Saint-Louis, Paris, France.

PMID: 33428440
DOI: 10.7326/L20-1051

No abstract available

Publication types

Case Reports

MeSH terms

Castleman Disease / diagnosis*
Castleman Disease / drug therapy*
Diagnostic Imaging
Humans
Male
Middle Aged
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib

Supplementary concepts

Multi-centric Castleman's Disease